AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Epicrispr Biotechnologies Closed A $90 Million Series C Financing Round, Led By Octagon Capital And Janus Henderson Investors, To Push Epi 321 Into Pivotal Trials. announced it raised $177 Million in an initial filing from an offering of $213 Million
Amount Raised
$177 Million
Round Type
Series C
San FranciscoBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Epicrispr Biotechnologies has secured a $90 million Series C financing round, oversubscribed and supported by a notable array of investors including Fidelity and Sanofi Ventures. This funding will focus on advancing EPI-321, its lead candidate for treating facioscapulohumeral muscular dystrophy, through pivotal clinical development. The company aims to demonstrate that gene silencing can become a viable therapeutic option without altering DNA. This significant investment reflects growing confidence in epigenetics as a therapeutic modality.
Fundz sees it the moment Epicrispr Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Epicrispr Biotechnologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.